Clinical correlates of clozapine prescription for schizophrenia in China

Human Psychopharmacology

Volumn 22, Issue 1, 2007, Pages 17-25

  Xiang, Yu Tao ^a,b   Weng, Yong Zhen ^b   Leung, Chi Ming ^a   Tang, Wai Kwong ^a   Ungvari, Gabor Sandor ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

China; Clozapine; Prescription patterns; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CHINA; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ACTIVITY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH INSURANCE; HONG KONG; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONSET AGE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; STRUCTURED INTERVIEW; SUICIDE ATTEMPT;

ADULT; AGE FACTORS; AKATHISIA, DRUG-INDUCED; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CHINA; CLOZAPINE; CROSS-CULTURAL COMPARISON; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HONG KONG; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RISK FACTORS; SCHIZOPHRENIA; STATISTICS; SUICIDE;

EID: 33846638791     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.821     Document Type: Article

References (51)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. (4th edn). American Psychiatric Association: Washington.
2. Andersen J, Larsen JK, Schultz V, et al. 1989. The Brief Psychiatric Rating Scale. Dimension of schizophrenia - reliability and construct validity. Psychopathology 22: 168-176.
3. Barnes TR. 1989, A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Browne S, Roe M, Lane A, et al. 1996. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 94: 118-124.
5. Carpenter WT, Jr., Conley RR, Buchanan RW, Breier A, Tamminga CA. 1995. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 152: 827-832.
6. Chan S, MacKenzie A, Ng TFD, Leung JKY. 2000. Evaluating the use of case management in community psychiatric nursing services in Hong Kong. J Adv Nurs 31: 144-156.
7. Cheng WZ. 1976. Clozapine. Shanghai Arch Psychiatry 4: 1-9.
8. Chinese Medical Association. 2003. Guidelines for the Prevention and Treatment of Mental Disorder. China Medical Association: Beijing.
9. Chong SA, Tan CH, Khoo YM, et al, 1997. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit 19: 219-223.
10. Chong MY, Tan CH, Fujii S, et al. 2004. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 58: 61-67.
11. Cohen J. 1988. Statistical Power Analysis for the Behavioral Sciences. (2nd edn). Erlbaum Hillsdale: NJ.
12. Corrigan PW, Buican B. 1995. The construct validity of subjective quality of life for the severely mentally ill. J Nerv Ment Dis 183: 281-285.
13. Fleischhacker WW, Hummer M, Kurz M, et al. 1994. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 55(Suppl B): 78-81.
14. Fu HP, Huo J, Wei HQ. 2004. The impact of olanzapine and clozapine on the quality of life in schizophrenia patients. J Clin Psychol Med 14: 104.
15. Gao SH, Ma JG, Xu FL, Yang SQ. 2002. The effectiveness of combination of clozapine and lithium carbonate in the treatment of chronic schizophrenia. Nerv Dis Ment Hyg 2: 338-339.
16. Hao YT, Fang JQ. 2000. The introduction and usage of WHOQOL instrument in Chinese. Mod Rehabil 4: 1127-1129.
17. Henderson DC, Goff DC. 1996. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57: 395-397.
18. HK. 2004. Annual Report 2002-2003. Hospital Authority Hong Kong: Hong Kong SAR, China.
19. Jin SL, Xie Z, Song CS, Lin RM, Luo Y. 2002. Investigation of the prescription of antipsychotics in three psychiatric hospitals. Shandong Arch Psychiatry 15: 46-47.
20. Kando JC, Tohen M, Castillo J, Centorrino F. 1994. Concurrent use of clozapine and valproate in affective and psychotic disorders, J Clin Psychiatry 55: 255-257.
21. Kane JM. 1996. Schizophrenia. N Engl J Med 334: 34-41.
22. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. 2001, Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 158: 311-314.
23. Liu TL, Li CY. 2003. The comparison of use of antipsychotics in first-episode patients with schizophrenia. Med J Chin People's Health 15: 289-290.
24. Lobana A, Mattoo SK, Basu D, Gupta N. 2001. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr Scand 104: 51-55.
25. Meltzer HY. 2005. Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J Clin Psychiatry 66: 530-533.
26. Novick D, Bousono M, Suarez D, et al. 2005. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Out-patients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry 29: 972-982.
27. O'Brien A. 2004. Starting clozapine in the community: a UK perspective. CNS Drugs 18: 845-852.
28. Phillips MR, Xiong W, Zhao ZA. 1990. Issues Involved in the Use of Scales for the Assessment of Negative and Positive Symptoms in Psychiatric Patients. Hubei Science and Technology Publishing House: Wuhan, PRC.
29. Phillips MR, Lu SH, Wang RW. 1997. Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Am J Psychiatry 154: 1228-1234.
30. Potter WZ, Ko GN, Zhang LD, Yan WW. 1989. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berl) 99: S87-S91.
31. Ran MS, Yu-Hai CE. 2004. Suicide and schizophrenia in China. Lancet 364: 1016-1017.
32. Remington G, Saha A, Chong SA, Shammi C. 2005. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 19: 843-872.
33. Rudnick A, Kravetz S. 2001. The relation of social support-seeking to quality of life in schizophrenia. J Nerv Ment Dis 189: 258-262.
34. Schuklenk U. 2001. Helsinki Declaration revisions. Issues Med Ethics 9; 29.
35. Shafer A. 2005. Meta-analysis of the brief psychiatric rating scale factor structure. Psychol Assess 17: 324-335.
36. Sim K, Su A, Fujii S, et al. 2004a. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58: 178-183.
37. Sim K, Su A, Leong JY, et al. 2004b. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 37: 175-179.
38. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212: 11-19.
39. Song CF. 2001. Analysis the first use of antipsychotics in the outpatients with first-episode schizophrenia. Sichuan Ment Health 14: 153-155.
40. Strejilevich SA, Palatnik A, Avila R, et al. 2005. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Res 133: 277-280.
41. Szegedi A, Anghelescu I, Wiesner J, et al. 1999. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32: 148-153.
42. Taylor D, Paton C, Kerwin R. 2003. The Maudsley Prescribing Guidelines. Martin Dunitz: London.
43. Ungvari GS, Chiu HF. 2004. The state of psychiatry in Hong Kong: a bird's eye view. Int J Soc Psychiatry 50: 5-9.
44. Ungvari GS, Chung Y, Chee Y, Fung-Shing N, Kwong T, Chiu H. 2002. The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999. Br J Clin Pharmacol 54: 437-444.
45. Weng YZ, Xu MJ, Li DL, Guo FY, Huang Q, Fu T. 2001. Assessment of expressed emotion in family members of schizophrenic patients in Beijing. Mod Rehabil 5: 39-42.
46. WHO. 1995. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41: 1403-1409.
47. WHO. 1998. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 28: 551-558.
48. Young CR, Longhurst JG, Bowers MB, Jr., Mazure CM. 1997. The expanding indications for clozapine. Exp Clin Psychopharmacol 5: 216-234.
49. Zhang GP, Wang CY. 2001. The one-day survey on psychotropic drugs use in 788 psychotic inpatients in Beijing Anding Hospital. Chin J Clin Pharmacol 17: 287-289.
50. Zhang SY, Yu HY, Wang GJ. 2001. Time-point investigation of diagnosis and its antipsychotics drug in mental inpatients. Sichuan Ment Health 14: 72-74.
51. Zhao JY, Shi YZ, Zhao XX, Lv LX, Guo SQ. 2002. Survey on psychotropic drug used in first-episode schizophrenics. Health Psychol J 10: 167-168.